China Galaxy released a research report on April 25 stating that it gave Biotech Co., Ltd. (600201.SH) a recommended rating. The main reasons for the rating include: 1) the company's revenue & profit growth in 23, and steady performance in 24Q1; 2) the gross margin of government harvesting increased significantly, and the growth rate of large individual pig seedlings was impressive; 3) continuous investment in research and development, and the world's first animal mRNA vaccine production workshop passed static inspection. (Mainichi Keizai Shimbun)
中国银河4月25日发布研报称，给予生物股份（600201.SH）推荐评级。评级理由主要包括：1）23年公司收入&盈利增长，24Q1业绩稳健；2）政采毛利率提升显著，猪苗大单品圆环、圆支增速亮眼；3）持续投入研发，全球首个动物mRNA疫苗生产车间通过静态验收。（每日经济新闻）
China Galaxy released a research report on April 25 stating that it gave Biotech Co., Ltd. (600201.SH) a recommended rating. The main reasons for the rating include: 1) the company's revenue & profit growth in 23, and steady performance in 24Q1; 2) the gr
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.